Activin and Inhibin

5-LOX-IN-4 is a 5-Lipoxygenase inhibitor extracted from patent EP 331232 A2, table 4, compound example 4.10.IC50&amp: Target:5-Lipoxygenase.

5-Phenylpentan-2-one is a potent histone deacetylases ( HDACs ) inhibitor. 5-Phenylpentan-2-one can be used for urea cycle disorder research.Form:Liquid.

5-Phenylpentan-2-one is a potent histone deacetylases ( HDACs ) inhibitor. 5-Phenylpentan-2-one can be used for urea cycle disorder research.Form:Liquid.

5-Phenylpentan-2-one is a potent histone deacetylases ( HDACs ) inhibitor. 5-Phenylpentan-2-one can be used for urea cycle disorder research.Form:Liquid.

5-Phenylpentan-2-one is a potent histone deacetylases ( HDACs ) inhibitor. 5-Phenylpentan-2-one can be used for urea cycle disorder research.Form:Liquid.

5-Phenylpentan-2-one is a potent histone deacetylases ( HDACs ) inhibitor. 5-Phenylpentan-2-one can be used for urea cycle disorder research.Form:Liquid.

5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1

5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 ( PFKFB4 ) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site ( K i =8.6 μM). 5MPN does not inhibit PFK-1